drugset
drugset / Trial / NCT06640166

Encorafenib + Cetuximab Beyond Progression in Combination With FOLFIRI in Patients With BRAF V600E Mutated Metastatic Colorectal Cancer Progressing on Encorafenib + Cetuximab.

NCT06640166 ↗

Phase 2 Recruiting 25 enrolled Fondazione Policlinico Universitario Agostino Gemelli IRCCS Pierre Fabre Pharma GmbH · collab
NaSingle-groupOpen-labelTreatment

Summary

The aim of this study is to determine the activity of encorafenib plus cetuximab in combination with FOLFIRI in patients with BRAF V600E mutated metastatic colorectal cancer progressing on encorafenib plus cetuximab administered in second line.

Timeline

Start
2024-06-03
Primary completion
2025-12-31
Completion
2026-06-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Cetuximab Monoclonal antibody 500 mg/m2 Intravenous
Subject Encorafenib Small molecule 300 mg Oral
Background Irinotecan Small molecule 180 mg/m2 Intravenous
Background Leucovorin Small molecule 400 mg/m2 Intravenous
Background fluorouracil Small molecule 400 mg/m2 Intravenous
Background fluorouracil Small molecule 2400 mg/m2 Intravenous

Indications

colon adenocarcinoma